Improving the effectiveness of H. pylori eradication therapy: focus on patient compliance and treatment safety

The aim was to evaluate the effect of the combined butyrate and inulin supplement administered as an adjuvant to Helicobacter pylori eradication therapy (ET) on treatment outcome. 349 patients with chronic gastroduodenal diseases and infected H. pylori were еxamined. A comparative analysis of the effect of a combined butyrate and inulin supplement on improving the effectiveness of the optimized ET regimen, improving its tolerability and patients’ compliance. The success of eradication was controlled by a 13C urease breath test. Significantly higher eradication rates were observed in the ET + combined butyrate and inulin supplement group (91,3% versus 74,4%, р˂ 0,05), compared with the control group (ET only). A lower incidence of side effects (bloating, rumbling, diarrhea, bitterness in the mouth) by the end of the 14-day course of treatment was noted in the ET + combined butyrate and inulin supplement group (p˂ 0,01). Significantly higher patient adherence rates (87% versus 63%, p = 0.04) and a lower discontinuation rates of ET (χ2 = 8.22, p = 0.0041) were also noted in the ET + combined butyrate and inulin supplement group, compared with control group (ET only). The adjuvant administration of a combined supplement of butyric acid and inulin to a standard three-component ET regimen significantly increases the effectiveness of treatment and is associated with less self-reported side effects (diarrhea, bloating, bitterness in the mouth), lower side effects-related treatment discontinuation rates and higher treatment compliance. 

1. Graham D. Y., Lee Y. C., Wu M. S. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence // Clin Gastroenterol Hepatol. 2014; 12: 177-186.

2. Plavnik R., Nevmerzhitskiy V., Embutniex Yu., Voynovan I., Kondrasheva E., Abdulova M, Bordin D. The prevalence of Helicobacter pylori in Russia // Helicobacter. 2018; 23 (S1): 24.

3. Wermeille J., Cunningham M., Girard L. et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? // Gastroenterol Clin Biol. 2002; 26 (3): 216-219.

4. Boltin D., Ben-Zvi H., Perets T. T., Kamenetsky Z., Samra Z., Dickman R., Niv Y. Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned? // J Clin Microbiol. 2015; 53: 522-527.

5. Ivashkin V. T., Mayev I. V., Lapina T. L., Sheptulin A. A., Trukhmanov A. S., Baranskaya Ye. K., Abdulkhakov R. A., Alekseyeva O. P., Alekseyenko S. A., Dekhnich N. N., Kozlov R. S., Klyaritskaya I. L., Korochanskaya N. V., Kurilovich S. A., Osipenko M. F., Simanenkov V. I., Tkachev A. V., Khlynov I. B., Tsukanov V. V. Klinicheskiye rekomendatsii Rossiyskoy gastroenterologicheskoy assotsiatsii po diagnostike i lecheniyu infektsii Helicobacter pylori u vzroslykh [Clinical guidelines of the Russian Gastroenterological Association for the diagnosis and treatment of Helicobacter pylori infection in adults] Ros. zhurn. gastroenterol. gepatol. koloproktol. 2018; 28 (1): 55-70.

6. Malfertheiner P., Megraud F., O’Morain C. A, Gisbert J. P., Kuipers E. J., Axon A. T., Bazzoli F., Gasbarrini A., Atherton J., Graham D. Y., Hunt R., Moayyedi P., Rokkas T., Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E. M. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report // Gut. 2017; 66: 6-30.

7. Livzan M. A. Podvodnyye kamni antikhelikobakternoy terapii [Pitfalls of anti-Helicobacter pylori therapy] Terapevticheskiy arkhiv. 2019; 91 (8): 141-147.

8. Peura D. A., Crowe S. E. Helicobacter pylori / Sleisenger & Fordtran’s gastrointestinal and liver disease / Eds. M. Feldman, L. S. Friedman, L. J. Brandt. 9th ed. Philadelphia, Pa: Saunders Elsevier, 2010: chap 50.

9. Hudson N., Brydon W. G., Eastwood M. A. et al. Successful H. pylori eradication incorporating a one-week antibiotic regimen // Aliment. Pharmacol. Ther. 1995. Vol. 9. P. 47-50.

10. Ford A. C., Gurusamy K. S., Delaney B., Forman D., Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pyloripositive people // Cochrane Database of Systematic Reviews. 2016, Issue 4. Art. No.: CD003840.

11. Beaugerie L., Petit J. C. Microbial-gut interactions in health and disease. Antibiotic-associated diarrhea // Best Pract Res Clin Gastroenterol. 2004; 18 (2): 337-352. DOI: 10.1016/j.bpg.2003.10.002. PMID: 15123074.

12. Yonezawa H., Osaki T., Hanawa T., Kurata S., Zaman C., Woo T. D. H., Takahashi M., Matsubara S., Kawakami H., Ochiai K., Kamiya S. Destructive effects of butyrate on the cell envelope of Helicobacter pylori // J Med Microbiol. 2012; 61 (Pt 4): 582-589. DOI: 10.1099/jmm.0.039040-0. Epub 2011 Dec 22. PMID: 22194341.

13. Takahashi M., Taguchi H., Yamaguchi H., Osaki T., Kamiya S. Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice // J Med Microbiol. 2000; 49 (7): 635-642. DOI: 10.1099/0022-1317-49-7-635. PMID: 10882089.

14. Li L., Zhou X., Xiao S., Ye F., Zhang G. The Effect of Helicobacter pylori Eradication on the Gastrointestinal Microbiota in Patients with Duodenal Ulcer // J Gastrointestin Liver Dis. 2016; 25 (2): 139-146. DOI: 10.15403/jgld.2014.1121.252.hpe. PMID: 27308643.

15. Yanagi H., Tsuda A., Matsushima M., et al. Changes in the gut microbiota composition and the plasma ghrelin level in patients with Helicobacter pylori-infected patients with eradication therapy // BMJ Open Gastro. 2017. P. 4 e000182.